← Eichor
Study identifier: NCT07246187 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Comparing Haloperidol to Olanzapine in the Treatment of Suspected Cannabinoid Hyperemesis in the Emergency Department

Condition: Cannabinoid Hyperemesis Syndrome  ·  Sponsor: Mercy Bon Secours Saint Vincent Medical Center

PhasePhase 3
Planned participants114
Who can joinAll sexes, 18 Years to 100 Years
Healthy volunteersNo

About this study

The aim of the study is to identify which medication (haloperidol or olanzapine) is most effective in treating nausea and abdominal pain associated with cannabinoid hyperemesis using a 10-point visual analog scale with intervals of 0.5.

This description comes directly from the study's public registry record.

Talk to the study team

Joseph Jabour, DO FACEP  ·  3303476487  ·  jabourj1@gmail.com

Amanda Gutek  ·  agutek@mercy.com

Always discuss trial participation with your own doctor first.

Locations (1)

Mercy Saint Vincent Medical CenterToledo, Ohio, United StatesRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07246187